XML 50 R14.htm IDEA: XBRL DOCUMENT

Reduction In Workforce	9 Months Ended
Reduction In Workforce	Sep. 30, 2012
Reduction In Workforce [Abstract]
Reduction In Workforce	8. Reduction in Workforce In March 2012, the Company implemented a reduction in its workforce of 11 full-time employees, primarily in research and development. The restructuring follows the discontinuation of the Company’s SCV-07 phase 2b clinical trial. The reduction in workforce resulted in severance-related charges of approximately $1.0 million, of which no expense was recognized in the condensed consolidated statement of operations for the three-month period ended September 30, 2012, and $0.1 million and $0.9 million was recognized in general and administrative and research and development expense, respectively, in the condensed consolidated statement of operations for the nine-month period ended September 30, 2012. As of September 30, 2012, the Company had paid $0.7 million and had accrued $0.3 million of the severance-related charges. The Company had substantially completed its restructuring activities as of September 30, 2012.